checkAd
    Startseite > Aktien > Valbiotis > Nachrichten
    Valbiotis Aktie
    3,9975
     
    EUR
    -0,12 %
    -0,0050 EUR
    Letzter Kurs 07:47:07 Lang & Schwarz
    3,8550
     
    EUR
    252 STK
    Geldkurs 07:47:07
    4,1400
     
    EUR
    252 STK
    Briefkurs 07:47:07
    ISIN: FR0013254851 · WKN: A2DS5F · Frankreich

    Neueste Nachrichten

    Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
    03.04.24 · EQS Group AG · Valbiotis
    Valbiotis announces the success of its €15 M capital increase
    22.12.23 · EQS Group AG · Valbiotis
    Valbiotis announces the launch of a capital increase
    11.12.23 · EQS Group AG · Valbiotis
    Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
    07.11.23 · EQS Group AG · Valbiotis
    VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
    02.10.23 · EQS Group AG · Valbiotis
    Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
    28.09.23 · EQS Group AG · Valbiotis
    VALBIOTIS SA: Valbiotis Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM•63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance
    11.09.23 · Accesswire · Valbiotis
    VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
    11.09.23 · EQS Group AG · Valbiotis
    Valbiotis announces its roadmap and strategic priorities on the eve of key milestones for its portfolio of innovative active substances
    12.07.23 · EQS Group AG · Valbiotis
    Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes
    23.05.23 · Business Wire (dt.) · Valbiotis
    Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
    22.05.23 · Business Wire (engl.) · Valbiotis
    Valbiotis – Combined Annual Shareholders General Meeting held on May 2, 2023
    03.05.23 · Business Wire (engl.) · Valbiotis